High-dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility

Acta Paediatr Scand. 1991 Feb;80(2):163-6. doi: 10.1111/j.1651-2227.1991.tb11828.x.

Abstract

Three newborn infants who developed hyperbilirubinemia due to blood group incompatibility were treated with high-dose gammaglobulin. Hyperbilirubinemia was caused by Rhesus (Rh) incompatibility (anti-E + anti-c) in Infant 1 and ABO incompatibility (anti-B) in Infants 2 and 3. Hyperbilirubinemia was refractory to conventional phototherapy but responded well to intravenous gammaglobulin (IVGG) at a dose of 1 g/kg in all infants. No adverse effects were observed. These findings suggest that high-dose IVGG may be useful in the treatment of hyperbilirubinemia due to isoimmune haemolytic disease resistant to phototherapy.

Publication types

  • Case Reports

MeSH terms

  • Drug Combinations
  • Erythroblastosis, Fetal / therapy*
  • Female
  • Fibrinolysin / administration & dosage*
  • Humans
  • Immunization, Passive*
  • Immunoglobulins, Intravenous
  • Infant, Newborn
  • Male
  • gamma-Globulins / administration & dosage*

Substances

  • Drug Combinations
  • Immunoglobulins, Intravenous
  • gamma-Globulins
  • Fibrinolysin